| Autor: |
Miriam Blasi, Daniel Kazdal, Michael Thomas, Petros Christopoulos, Mark Kriegsmann, Regine Brandt, Anna-Lena Volckmar, Martina Kirchner, Claus Peter Heußel, Albrecht Stenzinger, Jonas Kuon |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Case Reports in Oncology, Vol 14, Iss 1, Pp 477-482 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1662-6575 |
| DOI: |
10.1159/000513904 |
| Popis: |
Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The duration of the response is, however, limited in time owing to the development of resistance mechanisms to both first- and second-generation agents such as MET oncogene amplification. This report describes the successful results obtained with the combination of the third-generation TKI osimertinib with the multitargeted TKI and MET inhibitor crizotinib in a patient with EGFR-mutant NSCLC with emerging MET amplification with a tolerable toxicity profile. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
